Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors: evaluation of therapeutic and toxic effects

Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors : evaluation of therapeutic and toxic effects

Tiensuu Janson, Eva (author): Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi, K Öberg

Eriksson, Barbro (author): Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi, K Öberg

Öberg, Kjell (author): Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi, K Öberg

Skogseid, Britt (author): Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi, K Öberg

(creator_code:org_t)

2009-07-08
1999
English.
In: Acta Oncologica. - : Informa UK Limited. - 0284-186X .- 1651-226X. ; 38:3, s. 373-377

Related links:: https://www.tandfonl...; show more...; https://urn.kb.se/re...; https://doi.org/10.1...; show less...

Abstract Subject headings

Carcinoid tumors and endocrine pancreatic tumors often express somatostatin receptors (sst). Tumor spread may be visualized by sst scintigraphy using [(111)In-DTPA-D-Phe1]-octreotide. In this study, tumor targeting therapy with [(111)In-DTPA-D-Phe1]-octreotide at high doses (6 GBq every third week) was used to treat patients with sst-expressing tumors. Five patients entered the protocol and three were evaluable for response, while all could be evaluated for toxicity. Two patient responded with a significant reduction in tumor markers (> 50%). The third patient showed increasing levels of tumor markers. Side effects were expressed as depression of bone-marrow function. In one patient a grade 4 reduction in platelet count was observed requiring several thrombocyte transfusions. In another two patients platelet counts decreased significantly. We conclude that treatment with [(111)In-DTPA-D-Phe1]-octreotide can be used in patients with neuroendocrine tumors but blood parameters have to be carefully monitored to avoid severe side effects.

By the author/editor: Tiensuu Janson, ...; Eriksson, Barbro; Öberg, Kjell; Skogseid, Britt; Öhrvall, Ulf; Nilsson, Sten; show more...; Westlin, Jan-Eri ...; show less...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.